Shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) rose 2.4% on Wednesday . The company traded as high as $16.38 and last traded at $16.38, approximately 665 shares were traded during trading. An increase of 518% from the average daily volume of 108 shares. The stock had previously closed at $16.00.
BIOVF has been the topic of a number of analyst reports. Zacks Investment Research cut Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “sell” rating in a research report on Wednesday, September 25th. Deutsche Bank downgraded Swedish Orphan Biovitrum AB (publ) from a “buy” rating to a “hold” rating in a research note on Thursday, July 18th.
The business’s 50 day moving average is $16.37. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.75 and a quick ratio of 0.55.
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.